William Blair analyst Matt Phipps has maintained their bullish stance on EVMN stock, giving a Buy rating on April 10.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied to Evommune’s lead asset EVO756 and its emerging migraine franchise. He cites a substantial unmet need in migraine prevention, where current therapies leave many patients inadequately treated, and notes that targeting MRGPRX2 offers a differentiated mechanism that, despite limited existing data, is supported by encouraging early preclinical and clinical signals.
At the same time, he emphasizes that the most significant near‑term value driver is the forthcoming Phase IIb readout of EVO756 in chronic spontaneous urticaria, which has fully enrolled and is on schedule for data this quarter. In his view, this upcoming CSU catalyst, combined with the higher‑risk but high‑reward migraine program set to begin Phase IIb in 2026 with data expected in 2027, creates an attractive risk‑reward profile that justifies a Buy recommendation on Evommune, Inc.
According to TipRanks, Phipps is a 4-star analyst with an average return of 5.4% and a 43.29% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Insmed, Incyte, and Compass Therapeutics.
In another report released on April 10, RBC Capital also maintained a Buy rating on the stock with a $48.00 price target.